A5004158484- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- Medical Imaging Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
- Management of metastatic bone disease
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chemotherapy-induced cardiotoxicity and mitigation
- Lung Cancer Treatments and Mutations
- Medical Imaging and Pathology Studies
- Renal and related cancers
- Chronic Lymphocytic Leukemia Research
- Neuroendocrine Tumor Research Advances
Macquarie University
2016-2024
Nepean Hospital
2014-2024
Health and Human Development (2HD) Research Network
2018-2019
Westmead Hospital
2016-2017
Cancer Australia
2015
PURPOSE The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation PALLAS. METHODS Patients with stage II-III HR+, HER2– disease were randomly assigned 2 years ET versus alone. primary...
3023 Background: DB-1303 is an antibody-drug conjugate (ADC) consisting of a humanized anti-HER2 IgG1 monoclonal antibody, covalently linked to proprietary DNA topoisomerase I inhibitor (P1003) via maleimide tetrapeptide-based cleavable linker, with high drug-to-antibody ratio (~8). Methods: This global first-in-human, dose-escalation and -expansion study in patients (pts) advanced/metastatic solid tumors. Pts (ECOG 0-1) HER2 – (high or low) expressing mutant cancers who failed previously...
Palazestrant is a small molecule oral complete ER antagonist (CERAN) and selective degrader (SERD) that completely blocks ER-driven transcriptional activity. combined with ribociclib demonstrated activity in both ESR1-wt ESR1-mut models, brain metastasis animal models. In phase 1/2 monotherapy study of ER+, HER2- metastatic breast cancer (MBC) patients (pts), palazestrant was well tolerated, encouraging antitumor efficacy favorable pharmacokinetics (PK) at the 120 mg once daily (qd)...
Abstract Background Immunotherapy has historically been of interest in the management metastatic renal cell cancer (mRCC) because its relative chemoresistance and reproducible but low incidence spontaneous remission disease. Recently, targeted immunotherapies form checkpoint inhibitors have shown durable responses approximately 20%–30% patients with solid tumors, a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/programmed ligand antibodies rely on presence...
TPS1118 Background: HR+/HER2− advanced breast cancer that progresses on endocrine therapy is treated with chemotherapy (chemo). The phase 1b KEYNOTE-028 trial showed durable activity pembrolizumab (pembro) monotherapy in previously HR+/HER2−, PD-L1–positive (combined positive score [CPS] ≥1) cancer. KEYNOTE-B49 (NCT04895358) a 3, randomized, double-blind study of pembro + chemo vs placebo (pbo) centrally assessed PD-L1–positive, locally recurrent inoperable or metastatic (mBC) after...
A limitation to the wider introduction of personalised dosimetry in theranostics is relative paucity imaging radionuclides with suitable physical and chemical properties be paired a long-lived therapeutic partner. As most beta-emitting emit gamma radiation as well they could potentially used radionuclide radionuclide. However, downsides are that beta will deliver significant dose part treatment planning procedure, branching ratio often quite low. Gallium-67 has been use nuclear medicine for...
Abstract Aim Sunitinib is a first‐line treatment option for metastatic renal cell carcinoma (mRCC) funded by the Australian Pharmaceutical Benefits Scheme. Toxicities are common with standard schedule leading to alternative dosing schedules be suggested. We reviewed practices evaluate safety and outcomes of patients on 2 weeks on, 1 week off (2/1). Methods performed retrospective review 63 mRCC treated sunitinib 2/1 at four centers. Results Forty‐six (73%) initiated whereas 17 (27%) switched...
261 Background: Miltuximab is a chimeric antibody targeting Glypican-1 which overexpressed in prostate cancer. has shown promising safety and efficacy radioimmunotherapy models of Methods: Metastatic patients (prostate, pancreatic bladder) were dosed with unlabelled followed by the infusion 1 mg/250MBq 67 Ga-Miltuximab. Patients underwent whole body gamma SPECT/CT scans up to 144 hours post-infusion. Standard care imaging was performed at least 14 days before after participation. Safety...
Anthracycline therapy (ANT) is associated with cancer therapy-related cardiac dysfunction. Coronary flow velocity reserve (CFVR) has shown prognostic utility in non-cancer cohorts, but no data have been obtained a cardio-oncology setting. We investigated the acute effect of ANT on CFVR breast patients. A total 12 female patients undergoing had pre- and post-ANT assessment. significant decline occurred (baseline: 2.66 ± 0.41 vs post-ANT: 2.47 0.37, P = 0.016). This prospective study first to...
Radioimmunotherapy (i.e., the use of radiolabeled tumor targeting antibodies) is an emerging approach for diagnosis, therapy, and monitoring solid tumors. Often using paired agents, each same molecule, but labelled with imaging or therapeutic isotope, radioimmunotherapy has achieved promising clinical results in relatively radio-resistant tumors such as prostate. Several approaches to optimize efficacy, dose fractionation personalized dosimetry, have seen success. The optimization a is,...
e565 Background: Metastatic or recurrent cancer continues to be a challenge in patients with urogenital and pancreatic cancers despite the development of newer anti-androgen therapies. MIL-38 is an IgG1 murine monoclonal antibody directed against Glypican-1 (GPC-1). The proteoglycan GPC-1 upregulated prostate, bladder cell lines. Targeting tumor xenografts lack adverse events pre-clinical models suggest chimeric (chMIL-38) good candidate for both radioimmunotherapy antibody-drug conjugate...
<h3>Background</h3> YBL-006 is a novel human monoclonal antibody against programmed cell death 1 (PD-1). A first-in-human study was conducted to evaluate the safety, recommended phase 2 dose, and anti-tumor efficacy. We have previously presented interim results, here we present updated safety efficacy results based on data at end of study. <h3>Methods</h3> modified '3+3' design utilized for dose escalation (cohort A; CA) 0.5, 2, 5, 10 mg/kg. In expansion B; CB), 200 mg every weeks 300 3 were...
Miltuximab
The Australian clinical trials sector has grown steadily over the past decade, particularly with respect to early phase where Australia's research capacity, capability and quality of is revered. With an increase in number internationally sponsored projects being conducted Australia, setting, there been a corresponding growth sites conducting trials. researchers are guided by multitude codes, guidance statements which govern conduct Although international regarding exists, currently no single...